{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:02:58Z","timestamp":1767142978805,"version":"build-2238731810"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s12094-015-1456-y","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T04:33:14Z","timestamp":1450672394000},"page":"996-1004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Seom guidelines for the treatment of gastric cancer 2015"],"prefix":"10.1007","volume":"17","author":[{"given":"M.","family":"Martin-Richard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Custodio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Garc\u00eda-Gir\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gr\u00e1valos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pericay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Carrato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"key":"1456_CR1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.seminoncol.2004.04.021","volume":"31","author":"KD Crew","year":"2004","unstructured":"Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:450\u201364.","journal-title":"Semin Oncol"},{"key":"1456_CR2","author":"J Ferlay","year":"2014","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and Mortality Worldwire: IARC. 2014;. doi: 10.1002\/ijc.29210PMID:25220842 (Published online 9 October).","journal-title":"Cancer incidence and Mortality Worldwire: IARC"},{"key":"1456_CR3","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"1456_CR4","volume-title":"AJCC Cancer staging Manual","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Frilz AG, Greene FL, Trotti A, editors. AJCC Cancer staging Manual. 7th ed. New York: Springer; 2010.","edition":"7"},{"key":"1456_CR5","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","volume":"85","author":"JR Siewert","year":"1998","unstructured":"Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457\u20139.","journal-title":"Br J Surg"},{"key":"1456_CR6","doi-asserted-by":"crossref","unstructured":"Colquhoun A, Arnold M, Ferlay J, Goodman KJ,\u00a0Forman D,\u00a0Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015; 0:1\u20138.","DOI":"10.1136\/gutjnl-2014-308915"},{"key":"1456_CR7","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-10-2203","volume":"17","author":"MA Shah","year":"2011","unstructured":"Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17:2693\u2013701.","journal-title":"Clin Cancer Res"},{"key":"1456_CR8","doi-asserted-by":"crossref","unstructured":"Tan IB, Ivanova T, Lim KH, Ong CW,\u00a0Deng N,\u00a0Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141:476\u201385 (485 e1-11).","DOI":"10.1053\/j.gastro.2011.04.042"},{"key":"1456_CR9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","volume":"145","author":"Z Lei","year":"2013","unstructured":"Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145:554\u201365.","journal-title":"Gastroenterology"},{"key":"1456_CR10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","volume":"61","author":"N Deng","year":"2012","unstructured":"Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673\u201384.","journal-title":"Gut"},{"key":"1456_CR11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"1456_CR12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449\u201356.","journal-title":"Nat Med"},{"key":"1456_CR13","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1245\/s10434-010-1433-1","volume":"18","author":"KH Brettingham-Moore","year":"2011","unstructured":"Brettingham-Moore KH, Duong CP, Heriot AG, Thomas RJ, Phillips WA. Using gene expression profiling to predict response and prognosis in gastrointestinal cancers-the promise and the perils. Ann Surg Oncol. 2011;18:1484\u201391.","journal-title":"Ann Surg Oncol"},{"key":"1456_CR14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jso.22089","volume":"105","author":"J Wang","year":"2012","unstructured":"Wang J, Yu JC, Kang WM, Ma ZQ. Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. J Surg Oncol. 2012;105:400\u20134.","journal-title":"J Surg Oncol"},{"key":"1456_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12029-010-9207-3","volume":"43","author":"A Salem","year":"2012","unstructured":"Salem A, Hashem S, Mula-Hussain LY, Mohammed I, Nour A, Shelpai W, et al. Management strategies for locoregional recurrence in early-stage gastric cancer: retrospective analysis and comprehensive literature review. J Gastrointest Cancer. 2012;43:77\u201382.","journal-title":"J Gastrointest Cancer."},{"key":"1456_CR16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jamcollsurg.2007.07.013","volume":"206","author":"M Fujiwara","year":"2008","unstructured":"Fujiwara M, Kodera Y, Misawa K, Kinoshita M, Kinoshita T, Miura S, et al. Longterm outcomes of early-stage gastric carcinoma patients treated with laparoscopy-assisted surgery. J Am Coll Surg. 2008;206:138\u201343.","journal-title":"J Am Coll Surg"},{"key":"1456_CR17","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1111\/j.1349-7006.2008.00935.x","volume":"99","author":"Y Yamada","year":"2008","unstructured":"Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci. 2008;99:2193\u20139.","journal-title":"Cancer Sci"},{"key":"1456_CR18","doi-asserted-by":"crossref","unstructured":"Lo Nigro C, Monteverde M, Riba M, Lattanzio L,\u00a0Tonissi F,\u00a0Garrone O, et al. Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. Int J Oncol. 2010;37:1219\u201328.","DOI":"10.3892\/ijo_00000773"},{"key":"1456_CR19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s12032-013-0678-5","volume":"30","author":"Z Wang","year":"2013","unstructured":"Wang Z, Yan Z, Zhang B, Rao Z, Zhang Y, Liu J, et al. Identification of a 5-gene signature for clinical and prognostic prediction in gastric cancer patients upon microarray data. Med Oncol. 2013;30:678.","journal-title":"Med Oncol"},{"key":"1456_CR20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1245\/s10434-009-0854-1","volume":"17","author":"A Takeno","year":"2010","unstructured":"Takeno A, Takemasa I, Seno S, Yamasaki M, Motoori M, Miyata H, et al. Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer. Ann Surg Oncol. 2010;17:1033\u201342.","journal-title":"Ann Surg Oncol"},{"key":"1456_CR21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2013.0009","volume":"11","author":"VE Strong","year":"2013","unstructured":"Strong VE, D\u2019Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013;11:60\u20136.","journal-title":"J Natl Compr Canc Netw"},{"key":"1456_CR22","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s12094-011-0709-7","volume":"13","author":"C Gomez-Martin","year":"2011","unstructured":"Gomez-Martin C, Concha A, Corominas JM, Garc\u00eda-Caballero T, Garc\u00eda-Garc\u00eda E, Iglesias M, et al. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Trans Oncol. 2011;13:636\u201351.","journal-title":"Clin Trans Oncol"},{"key":"1456_CR23","doi-asserted-by":"crossref","unstructured":"Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev.2015;2:CD009944.","DOI":"10.1002\/14651858.CD009944.pub2"},{"key":"1456_CR24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jso.23632","volume":"110","author":"JP Andrade De","year":"2014","unstructured":"De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol. 2014;110:291\u20137.","journal-title":"J Surg Oncol"},{"key":"1456_CR25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2967\/jnumed.114.150946","volume":"56","author":"Y Kaneko","year":"2015","unstructured":"Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. J Nucl Med. 2015;56:523\u20139.","journal-title":"J Nucl Med"},{"key":"1456_CR26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10120-013-0259-5","volume":"17","author":"H Shimada","year":"2014","unstructured":"Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26\u201333.","journal-title":"Gastric Cancer"},{"key":"1456_CR27","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/bjs.7033","volume":"97","author":"T Gotoda","year":"2010","unstructured":"Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg. 2010;97:868\u201371.","journal-title":"Br J Surg"},{"key":"1456_CR28","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4253\/wjge.v7.i12.1062","volume":"7","author":"J Espinel","year":"2015","unstructured":"Espinel J, Pinedo E, Ojeda V, Del Rio MG. Treatment modalities for early gastric cancer. World J Gastrointest Endosc. 2015;7:1062\u20139.","journal-title":"World J Gastrointest Endosc."},{"key":"1456_CR29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","volume":"11","author":"I Songun","year":"2010","unstructured":"Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439\u201349.","journal-title":"Lancet Oncol."},{"key":"1456_CR30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jso.23325","volume":"107","author":"L Jiang","year":"2013","unstructured":"Jiang L, Yang KH, Guan QL, Zhao P, Chen Y, Tian JH. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis. J Surg Oncol. 2013;107:807\u201314.","journal-title":"J Surg Oncol"},{"key":"1456_CR31","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","volume":"28","author":"C Schuhmacher","year":"2010","unstructured":"Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210\u20138.","journal-title":"J Clin Oncol"},{"key":"1456_CR32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681\u201392.","journal-title":"Lancet Oncol."},{"key":"1456_CR33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","volume":"27","author":"M Stahl","year":"2009","unstructured":"Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851\u20136.","journal-title":"J Clin Oncol"},{"key":"1456_CR34","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090\u20138.","journal-title":"Lancet Oncol."},{"key":"1456_CR35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"1456_CR36","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, Conroy T, Bouch\u00e9 O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715\u201321.","journal-title":"J Clin Oncol"},{"key":"1456_CR37","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.ejca.2013.05.029","volume":"49","author":"U Ronellenfitsch","year":"2013","unstructured":"Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49:3149\u201358.","journal-title":"Eur J Cancer"},{"key":"1456_CR38","doi-asserted-by":"crossref","unstructured":"Cunningham D, Smyth E, Stenning S. Perioperative chemotherapy- bevacizumab for resectable gastro-esophageal adenocarcinoma: Results from the UK Medical Research Council randomised T03 trial (ISRCTN 46020948). Eur J Cancer. 2015;51 (supplS3:Abstract2201).","DOI":"10.1016\/S0959-8049(16)31118-2"},{"key":"1456_CR39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","volume":"345","author":"JS Macdonald","year":"2001","unstructured":"Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725\u201330.","journal-title":"N Engl J Med"},{"key":"1456_CR40","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","volume":"30","author":"SR Smalley","year":"2012","unstructured":"Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327\u201333.","journal-title":"J Clin Oncol"},{"key":"1456_CR41","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.2010.534","volume":"303","author":"G Group","year":"2010","unstructured":"Group G, Paoletti X, Oba K, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729\u201337.","journal-title":"JAMA"},{"key":"1456_CR42","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"1456_CR43","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387\u201393.","journal-title":"J Clin Oncol"},{"key":"1456_CR44","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389\u201396.","journal-title":"Lancet Oncol."},{"key":"1456_CR45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","volume":"30","author":"J Lee","year":"2012","unstructured":"Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268\u201373.","journal-title":"J Clin Oncol"},{"key":"1456_CR46","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2014.58.3930","volume":"33","author":"SH Park","year":"2015","unstructured":"Park SH, Sohn TS, Lee J, Lim do H, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33:3130\u20136.","journal-title":"J Clin Oncol"},{"key":"1456_CR47","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903\u20139.","journal-title":"J Clin Oncol"},{"key":"1456_CR48","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Cutsem Van","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991\u20137.","journal-title":"J Clin Oncol"},{"key":"1456_CR49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36\u201346.","journal-title":"N Engl J Med"},{"key":"1456_CR50","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435\u201342.","journal-title":"J Clin Oncol"},{"key":"1456_CR51","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666\u201373.","journal-title":"Ann Oncol"},{"key":"1456_CR52","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547\u201353.","journal-title":"J Clin Oncol"},{"key":"1456_CR53","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/annonc\/mdn166","volume":"19","author":"M Dank","year":"2008","unstructured":"Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450\u20137.","journal-title":"Ann Oncol"},{"key":"1456_CR54","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"R Guimbaud","year":"2014","unstructured":"Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andr\u00e9 T, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32:3520\u20136.","journal-title":"J Clin Oncol"},{"key":"1456_CR55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"1456_CR56","doi-asserted-by":"crossref","first-page":"e108940","DOI":"10.1371\/journal.pone.0108940","volume":"9","author":"R Iacovelli","year":"2014","unstructured":"Iacovelli R, Pietrantonio F, Farcomeni A, et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One. 2014;9:e108940.","journal-title":"PLoS One"},{"key":"1456_CR57","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/annonc\/mdt351","volume":"24","author":"HS Kim","year":"2013","unstructured":"Kim HS, Kim HJ, Kim SY, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol. 2013;24:2850\u20134.","journal-title":"Ann Oncol"},{"key":"1456_CR58","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"47","author":"PC Thuss-Patience","year":"2011","unstructured":"Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2013a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306\u201314.","journal-title":"Eur J Cancer"},{"key":"1456_CR59","doi-asserted-by":"crossref","unstructured":"Kang JH, Lee SI, Lim do H et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30:1513\u20138.","DOI":"10.1200\/JCO.2011.39.4585"},{"key":"1456_CR60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HE Ford","year":"2014","unstructured":"Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78\u201386.","journal-title":"Lancet Oncol"},{"key":"1456_CR61","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438\u201344.","journal-title":"J Clin Oncol"},{"key":"1456_CR62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet"},{"key":"1456_CR63","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335.","journal-title":"Lancet Oncol"},{"key":"1456_CR64","unstructured":"TDM1 vs taxane in Previously Treated Advanced HER2+ Gastric Cancer study. In NCT06419391."},{"key":"1456_CR65","unstructured":"JACOB Study Pertuzumab With Trastuzumab and Chemotherapy in Patients With HER2+ Metastasic Gastric and Gastroesophageal Cancer In NCT01774786."},{"key":"1456_CR66","doi-asserted-by":"crossref","unstructured":"Cunningham D TN, Davidenko I. Phase III randomized double-blind multicenter, placebo cotrolled tiral of Rilotumumab plus epirrubicin, Cisplatin and Capecitibine (ECX) as first line therapy in patients with advanced MET\u2013positive gastric or gastroesophageal Junction Cancer: RILOMET 1 Study. J Clin Oncol. 2015;33(suppl; abstr 4000).","DOI":"10.1200\/jco.2015.33.15_suppl.4000"},{"key":"1456_CR67","doi-asserted-by":"crossref","unstructured":"Shah MCJ, BEeIT. Randomized Phase II Study of FOLFOX +\/- MET inhibitor, Ornatuzumab in advanced gastroesophageal adenocarcinoma (GEC). J Clin Oncol. 2015;33(suppl 3; abstr 2).","DOI":"10.1200\/jco.2015.33.3_suppl.2"},{"key":"1456_CR68","doi-asserted-by":"crossref","unstructured":"Segal NHAS, Brahmer JR. Preliminary Data from a multi arm expansion study of MEDI 4736, an anti PDL1 antibody. J CLin Oncol. 2014;32(15 suppl)134136\u2013144.","DOI":"10.1200\/jco.2014.32.15_suppl.3002"},{"key":"1456_CR69","doi-asserted-by":"crossref","unstructured":"Muro K, Bang YJ, Shankaran V, et al. Relationship between PDL1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti PDL1 monoclonal antibody Pembrolizumab in KEYNOTE-012. J Clin Oncol. 33(Suppl 3; abstr 3).","DOI":"10.1200\/jco.2015.33.3_suppl.3"},{"key":"1456_CR70","unstructured":"IGCC Working Group. The charter Scaligero on gastric cancer: follow up after gastrectomy for cancer. In: 10th international gastric cancer congress (IGCC) 2013."}],"updated-by":[{"DOI":"10.1007\/s12094-016-1491-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T00:00:00Z","timestamp":1455148800000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1456-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-015-1456-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-015-1456-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T20:42:16Z","timestamp":1653856936000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-015-1456-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1007\/s12094-015-1456-y","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}